| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
|
Lancet Oncol
|
2009
|
5.19
|
|
2
|
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).
|
J Clin Oncol
|
2003
|
2.97
|
|
3
|
UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer.
|
Clin Pharmacol Ther
|
2004
|
2.14
|
|
4
|
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
|
Pharmacogenet Genomics
|
2007
|
2.01
|
|
5
|
Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial.
|
Jpn J Clin Oncol
|
2006
|
1.88
|
|
6
|
Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma.
|
Gastric Cancer
|
2011
|
1.35
|
|
7
|
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
|
J Clin Oncol
|
2006
|
1.34
|
|
8
|
Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study.
|
Jpn J Clin Oncol
|
2004
|
1.26
|
|
9
|
Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples.
|
Cancer Sci
|
2008
|
1.23
|
|
10
|
Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
|
Clin Cancer Res
|
2008
|
1.19
|
|
11
|
Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC).
|
Cancer Chemother Pharmacol
|
2010
|
1.16
|
|
12
|
Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer.
|
Oncology
|
2008
|
1.11
|
|
13
|
Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan.
|
Pharmacogenetics
|
2003
|
1.11
|
|
14
|
Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population.
|
Hum Mutat
|
2004
|
1.03
|
|
15
|
Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene.
|
Int J Clin Oncol
|
2009
|
1.03
|
|
16
|
Characteristics and outcomes of patients with advanced gastric cancer who declined to participate in a randomized clinical chemotherapy trial.
|
J Oncol Pract
|
2011
|
1.02
|
|
17
|
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
|
Cancer Chemother Pharmacol
|
2009
|
1.01
|
|
18
|
Small cell carcinoma of the esophagus. Analysis of 14 cases and literature review.
|
Hepatogastroenterology
|
2005
|
0.99
|
|
19
|
Genetic variations and haplotypes of UGT1A4 in a Japanese population.
|
Drug Metab Pharmacokinet
|
2005
|
0.97
|
|
20
|
Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15.
|
Drug Metab Pharmacokinet
|
2007
|
0.97
|
|
21
|
Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences.
|
J Hum Genet
|
2007
|
0.96
|
|
22
|
Vesicocutaneous fistula formation during treatment with sunitinib malate: Case report.
|
BMC Gastroenterol
|
2010
|
0.95
|
|
23
|
Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
|
Int J Cancer
|
2011
|
0.95
|
|
24
|
Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202).
|
Int J Clin Oncol
|
2008
|
0.94
|
|
25
|
A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer.
|
Jpn J Clin Oncol
|
2009
|
0.93
|
|
26
|
A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer.
|
Jpn J Clin Oncol
|
2006
|
0.93
|
|
27
|
Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
|
Drug Metab Dispos
|
2008
|
0.91
|
|
28
|
Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction.
|
Jpn J Clin Oncol
|
2008
|
0.91
|
|
29
|
Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
|
Jpn J Clin Oncol
|
2009
|
0.89
|
|
30
|
Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients.
|
Cancer Lett
|
2007
|
0.89
|
|
31
|
Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine.
|
Gastric Cancer
|
2009
|
0.89
|
|
32
|
A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).
|
Gastric Cancer
|
2011
|
0.89
|
|
33
|
Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial.
|
Jpn J Clin Oncol
|
2004
|
0.89
|
|
34
|
Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.
|
Int J Clin Oncol
|
2003
|
0.89
|
|
35
|
Retrospective analysis of clinical results and predictors of response in chemo-naive patients with advanced gastric cancer treated with S-1, an oral fluoropyrimidine derivative, as single-agent chemotherapy.
|
Gastric Cancer
|
2004
|
0.89
|
|
36
|
Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.
|
Int J Clin Oncol
|
2012
|
0.88
|
|
37
|
Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
|
Jpn J Clin Oncol
|
2008
|
0.88
|
|
38
|
Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis.
|
J Cancer Res Clin Oncol
|
2010
|
0.88
|
|
39
|
Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
|
Br J Clin Pharmacol
|
2010
|
0.87
|
|
40
|
Novel genetic polymorphisms in the NR3C1 (glucocorticoid receptor) gene in a Japanese population.
|
Drug Metab Pharmacokinet
|
2005
|
0.87
|
|
41
|
Fourteen novel genetic variations and haplotype structures of the TYMS gene encoding human thymidylate synthase (TS).
|
Drug Metab Pharmacokinet
|
2006
|
0.87
|
|
42
|
Eight novel single nucleotide polymorphisms in ABCG2/BCRP in Japanese cancer patients administered irinotacan.
|
Drug Metab Pharmacokinet
|
2003
|
0.86
|
|
43
|
Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines.
|
Jpn J Clin Oncol
|
2007
|
0.86
|
|
44
|
Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.
|
J Pharmacol Exp Ther
|
2003
|
0.86
|
|
45
|
Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts.
|
Cancer Sci
|
2004
|
0.86
|
|
46
|
Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer.
|
Oncology
|
2008
|
0.85
|
|
47
|
Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912.
|
Gastric Cancer
|
2013
|
0.85
|
|
48
|
Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population.
|
Drug Metab Pharmacokinet
|
2006
|
0.85
|
|
49
|
Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.
|
Gastric Cancer
|
2010
|
0.85
|
|
50
|
Identification of the NEDD4L gene as a prognostic marker by integrated microarray analysis of copy number and gene expression profiling in non-small cell lung cancer.
|
Ann Surg Oncol
|
2013
|
0.84
|
|
51
|
Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data.
|
J Biosci Bioeng
|
2013
|
0.84
|
|
52
|
Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer.
|
Gastric Cancer
|
2000
|
0.84
|
|
53
|
Genetic polymorphisms of UGT1A6 in a Japanese population.
|
Drug Metab Pharmacokinet
|
2005
|
0.84
|
|
54
|
Functional analysis of four naturally occurring variants of human constitutive androstane receptor.
|
Mol Genet Metab
|
2005
|
0.83
|
|
55
|
Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population.
|
Drug Metab Pharmacokinet
|
2008
|
0.82
|
|
56
|
Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
|
Int J Cancer
|
2008
|
0.81
|
|
57
|
Haplotypes and a novel defective allele of CES2 found in a Japanese population.
|
Drug Metab Dispos
|
2007
|
0.81
|
|
58
|
Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
|
Jpn J Clin Oncol
|
2006
|
0.81
|
|
59
|
Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.
|
Anticancer Res
|
2005
|
0.81
|
|
60
|
Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors.
|
Int J Clin Oncol
|
2009
|
0.81
|
|
61
|
Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer.
|
Gastric Cancer
|
2013
|
0.81
|
|
62
|
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.
|
Cancer Chemother Pharmacol
|
2007
|
0.80
|
|
63
|
Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2).
|
Drug Metab Dispos
|
2005
|
0.80
|
|
64
|
Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin.
|
Jpn J Clin Oncol
|
2007
|
0.80
|
|
65
|
A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.
|
Cancer Chemother Pharmacol
|
2015
|
0.80
|
|
66
|
Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
|
Int J Clin Oncol
|
2004
|
0.79
|
|
67
|
Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer.
|
Jpn J Clin Oncol
|
2003
|
0.79
|
|
68
|
A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
|
Jpn J Clin Oncol
|
2008
|
0.79
|
|
69
|
Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer.
|
Cancer Sci
|
2009
|
0.79
|
|
70
|
Ectopic hepatocellular carcinoma of the left sub-diaphragm with metastasis.
|
Intern Med
|
2011
|
0.79
|
|
71
|
Three novel single nucleotide polymorphisms in UGT1A9.
|
Drug Metab Pharmacokinet
|
2003
|
0.78
|
|
72
|
Long-term results for patients with unresectable gastric cancer who received chemotherapy in the Japan Clinical Oncology Group (JCOG) trials.
|
Gastric Cancer
|
2000
|
0.78
|
|
73
|
Combination of O6-methylguanine-DNA methyltransferase and thymidylate synthase for the prediction of fluoropyrimidine efficacy.
|
Eur J Cancer
|
2007
|
0.78
|
|
74
|
A multicenter phase-II study of 5-FU, leucovorin and oxaliplatin (FOLFOX6) in patients with pretreated metastatic colorectal cancer.
|
Jpn J Clin Oncol
|
2010
|
0.78
|
|
75
|
[Predicting drug efficacy-fluorinated pyrimidines (fluorouracil, S-1 and capecitabine)].
|
Gan To Kagaku Ryoho
|
2012
|
0.78
|
|
76
|
Genetic variations of the AHR gene encoding aryl hydrocarbon receptor in a Japanese population.
|
Drug Metab Pharmacokinet
|
2004
|
0.77
|
|
77
|
Twenty-six novel single nucleotide polymorphisms and their frequencies of the NR1I3 (CAR) gene in a Japanese population.
|
Drug Metab Pharmacokinet
|
2003
|
0.77
|
|
78
|
Functional analysis of six human aryl hydrocarbon receptor variants in a Japanese population.
|
Drug Metab Dispos
|
2005
|
0.77
|
|
79
|
Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan.
|
Support Care Cancer
|
2003
|
0.76
|
|
80
|
A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
|
Jpn J Clin Oncol
|
2008
|
0.76
|
|
81
|
Phase II study of biweekly irinotecan and mitomycin C combination therapy in patients with fluoropyrimidine-resistant advanced colorectal cancer.
|
Cancer Chemother Pharmacol
|
2003
|
0.76
|
|
82
|
Relationship between expression of vascular endothelial growth factor in tumor tissue from gastric cancers and chemotherapy effects: comparison between S-1 alone and the combination of S-1 plus CDDP.
|
Jpn J Clin Oncol
|
2007
|
0.76
|
|
83
|
Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2).
|
Drug Metab Pharmacokinet
|
2003
|
0.75
|
|
84
|
CD34-negative solitary fibrous tumour resistant to imatinib.
|
BMJ Case Rep
|
2013
|
0.75
|
|
85
|
Successful Cord Blood Stem Cell Transplantation for an Adult Case of Chronic Active Epstein-Barr Virus Infection.
|
Intern Med
|
2016
|
0.75
|
|
86
|
A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703).
|
Jpn J Clin Oncol
|
2003
|
0.75
|
|
87
|
Three novel single nucleotide polymorphisms in UGT1A10.
|
Drug Metab Pharmacokinet
|
2002
|
0.75
|
|
88
|
Toxoplasmic Encephalitis with Untreated Hairy Cell Leukemia Variant.
|
Intern Med
|
2016
|
0.75
|
|
89
|
Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil.
|
Int J Clin Oncol
|
2004
|
0.75
|
|
90
|
[S-1 plus cisplatin(SP) for advanced gastric cancer].
|
Nihon Rinsho
|
2015
|
0.75
|
|
91
|
[Standard chemotherapy of solid tumors. 2) Cancers of the digestive system].
|
Nihon Naika Gakkai Zasshi
|
2009
|
0.75
|
|
92
|
[Neoadjuvant therapy for esophageal cancer - indication and efficacy].
|
Gan To Kagaku Ryoho
|
2007
|
0.75
|
|
93
|
[Toxicities associated with chemotherapy in colorectal cancer].
|
Nihon Rinsho
|
2003
|
0.75
|
|
94
|
Phase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors.
|
Jpn J Clin Oncol
|
2003
|
0.75
|
|
95
|
Effect of a 3-hour interval between methotrexate and 5-fluorouracil in the treatment of metastatic colorectal cancer.
|
Jpn J Clin Oncol
|
2002
|
0.75
|
|
96
|
Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients.
|
Anticancer Res
|
2014
|
0.75
|
|
97
|
Functional characterization of wild-type and variant (T202I and M59I) human UDP-glucuronosyltransferase 1A10.
|
Drug Metab Dispos
|
2003
|
0.75
|
|
98
|
Prognostic factors for patients with metastatic colorectal cancer receiving protracted venous infusion of 5-FU.
|
Am J Clin Oncol
|
2002
|
0.75
|
|
99
|
[S-1 as a single agent for colorectal cancer].
|
Gan To Kagaku Ryoho
|
2006
|
0.75
|
|
100
|
[Oncology at medical school].
|
Gan To Kagaku Ryoho
|
2008
|
0.75
|
|
101
|
[Hypofibrinogenemia associated with steroid therapy for the patients who developed GVHD after allogeneic stem cell transplantation].
|
Rinsho Ketsueki
|
2015
|
0.75
|
|
102
|
Long-term survivor of gastric small cell carcinoma.
|
Hepatogastroenterology
|
2004
|
0.75
|
|
103
|
Two Elderly Patients with Philadelphia Chromosome Positive Mixed Phenotype Acute Leukemia Who Were Successfully Treated with Dasatinib and Prednisolone.
|
Intern Med
|
2016
|
0.75
|